Clinical Trials Directory

Trials / Unknown

UnknownNCT05750979

Quantifying Disease Progression in LBSL

Quantifying Disease Progression in Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation (LBSL)

Status
Unknown
Phase
Study type
Observational
Enrollment
20 (estimated)
Sponsor
M. Engelen · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Accepted

Summary

Leukoencephalopathy with brain stem involvement and lactate elevation (LBSL) is a genetic disorder caused by biallelic mutations in the DARS2 gene that encodes mitochondrial aspartyl tRNA synthase.(1, 2) It is characterized by typical abnormalities on MRI of the brain and spinal cord.(3) Clinically, the disorder is heterogeneous and can present in the neonatal period, later in childhood or even in adults.(3) In general it can be stated that the earlier presentations are characterized by rapid progression leading to severe disability and death. Presentation at a later age is typically characterized by a more benign disease course, although considerable disability is common. Clinically, the disease presents as a slowly progressive myelopathy with mainly involvement of the corticospinal tracts and the dorsal columns. Although the natural history has been studied in large cohorts, the rate of progression has not been systematically studied with clinimetric outcome scales or potential surrogate outcomes for spinal cord disease.

Conditions

Timeline

Start date
2021-03-11
Primary completion
2025-12-31
Completion
2025-12-31
First posted
2023-03-02
Last updated
2023-03-02

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT05750979. Inclusion in this directory is not an endorsement.

Quantifying Disease Progression in LBSL (NCT05750979) · Clinical Trials Directory